• Segment growth trends: Lubricant packaging sales are expected to end flat or slightly negative due to West Asia conflicts affecting base oil supplies, while paints, food/FMCG, and pharma (over 25% growth) support a full-year volume growth target of 10% to 12%.
• Pharma segment expansion: Pharma revenue is projected to reach ₹50 to ₹55 crore in FY27 at an EBITDA of ₹100 to ₹120 per kg, with 30% to 40% growth expected in FY28 driven by the launch of an ophthalmic packaging range.
• EBITDA margin targets: The company targets around 20% EBITDA growth and an upgraded EBITDA per kg target near ₹45, supported by operational efficiencies from Hyderabad unit consolidation and monthly raw material cost pass-throughs.
• Capacity and new ventures: A 10% annual capacity expansion is scheduled to be operational by January, while commercial sales for high-value export products from the WypGen joint venture are slated to begin in the next financial year.
• Bonus and dividend: The board approved a 1:1 bonus share issue subject to shareholder approval and raised the dividend to a total of ₹5 per share.